Protocol Ledger

NCT04382664 · Phase II · COMPLETED

UV1 Vaccination Plus Nivolumab and Ipilimumab in Treatment of Melanoma

Interventional Phase II clinical trial protocol NCT04382664 sponsored by Ultimovacs ASA in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2020-05-27 Enrollment: 156 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT04382664
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)156 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)3 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT04382664
Protocol FieldVerified Registry Value
NCT IdentifierNCT04382664
Consolidated Lead SponsorUltimovacs ASA
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusCOMPLETED
Registered Enrollment156 participants (ACTUAL)
Registered Start Date2020-05-27
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI